Literature DB >> 18827960

Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy.

Pamela Mangat1, Samuel Whittle, Les Cleland, Vidya Limaye.   

Abstract

Anti-tumour necrosis factor alpha therapy has led to significant advancement in the treatment of rheumatological disease. Rarely, anti-TNFalpha antagonists have been associated with vasculitis, predominantly cutaneous leukocytoclastic vasculitis. We present the first case of angiographically-confirmed digital vasculitis occurring as a late complication of etanercept therapy. Our case adds to the limited repertoire of case reports of anti-TNFalpha induced vasculitis and highlights the potential risk of this serious complication occurring up to several years after initiation of these agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827960     DOI: 10.1007/s10067-008-1015-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Anti-tumour necrosis factor therapy associated with cutaneous vasculitis.

Authors:  P A Livermore; K J Murray
Journal:  Rheumatology (Oxford)       Date:  2002-12       Impact factor: 7.580

Review 2.  Problems encountered during anti-tumour necrosis factor therapy.

Authors:  Sheetal B Desai; Daniel E Furst
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-08       Impact factor: 4.098

Review 3.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.

Authors:  Michael B Stokes; Kirk Foster; Glen S Markowitz; Farhang Ebrahimi; William Hines; Darren Kaufman; Brooke Moore; Daniel Wolde; Vivette D D'Agati
Journal:  Nephrol Dial Transplant       Date:  2005-04-19       Impact factor: 5.992

6.  Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.

Authors:  Bernadette Saint Marcoux; Michel De Bandt
Journal:  Joint Bone Spine       Date:  2006-08-30       Impact factor: 4.929

7.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

Authors:  Niveditha Mohan; Evelyne T Edwards; Thomas R Cupps; Nancy Slifman; Jong-Hoon Lee; Jeffrey N Siegel; M Miles Braun
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

Review 8.  Tumor necrosis factor-alpha antagonists and neuropathy.

Authors:  Joerg-Patrick Stübgen
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217

  8 in total
  1 in total

Review 1.  Vasculitis induced by biological agents used in rheumatology practice: A systematic review.

Authors:  Camila da Silva Cendon Duran; Adriane Souza da Paz; Mittermayer Barreto Santiago
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.